TY - JOUR
T1 - INSPIRE
T2 - A European training network to foster research and training in cardiovascular safety pharmacology
AU - Guns, Pieter-Jan D.
AU - Guth, Brian D.
AU - Braam, Stefan
AU - Kosmidis, Georgios
AU - Matsa, Elena
AU - Delaunois, Annie
AU - Gryshkova, Vitalina
AU - Bernasconi, Sylvain
AU - Knot, Harm J.
AU - Shemesh, Yair
AU - Chen, Alon
AU - Markert, Michael
AU - Fernandez, Miguel A.
AU - Lombardi, Damiano
AU - Grandmont, Celine
AU - Cillero-Pastor, Berta
AU - Heeren, Ron M. A.
AU - Martinet, Wim
AU - Woolard, Jeanette
AU - Skinner, Matt
AU - Segers, Vincent F. M.
AU - Franssen, Constantijn
AU - Van Craenenbroeck, Emeline M.
AU - Volders, Paul G. A.
AU - Pauwelyn, Thomas
AU - Braeken, Dries
AU - Yanez, Paz
AU - Correll, Krystle
AU - Yang, Xi
AU - Prior, Helen
AU - Kismihok, Gabor
AU - De Meyer, Guido R. Y.
AU - Valentin, Jean-Pierre
PY - 2020/9
Y1 - 2020/9
N2 - Safety pharmacology is an essential part of drug development aiming to identify, evaluate and investigate undesirable pharmacodynamic properties of a drug primarily prior to clinical trials. In particular, cardiovascular adverse drug reactions (ADR) have halted many drug development programs. Safety pharmacology has successfully implemented a screening strategy to detect cardiovascular liabilities, but there is room for further refinement. In this setting, we present the INSPIRE project, a European Training Network in safety pharmacology for Early Stage Researchers (ESRs), funded by the European Commission's H2020-MSCA-ITN programme. INSPIRE has recruited 15 ESR fellows that will conduct an individual PhD-research project for a period of 36 months. INSPIRE aims to be complementary to ongoing research initiatives. With this as a goal, an inventory of collaborative research initiatives in safety pharmacology was created and the ESR projects have been designed to be complementary to this roadmap. Overall, INSPIRE aims to improve cardiovascular safety evaluation, either by investigating technological innovations or by adding mechanistic insight in emerging safety concerns, as observed in the field of cardio-oncology. Finally, in addition to its hands-on research pillar, INSPIRE will organize a number of summer schools and workshops that will be open to the wider community as well. In summary, INSPIRE aims to foster both research and training in safety pharmacology and hopes to inspire the future generation of safety scientists.
AB - Safety pharmacology is an essential part of drug development aiming to identify, evaluate and investigate undesirable pharmacodynamic properties of a drug primarily prior to clinical trials. In particular, cardiovascular adverse drug reactions (ADR) have halted many drug development programs. Safety pharmacology has successfully implemented a screening strategy to detect cardiovascular liabilities, but there is room for further refinement. In this setting, we present the INSPIRE project, a European Training Network in safety pharmacology for Early Stage Researchers (ESRs), funded by the European Commission's H2020-MSCA-ITN programme. INSPIRE has recruited 15 ESR fellows that will conduct an individual PhD-research project for a period of 36 months. INSPIRE aims to be complementary to ongoing research initiatives. With this as a goal, an inventory of collaborative research initiatives in safety pharmacology was created and the ESR projects have been designed to be complementary to this roadmap. Overall, INSPIRE aims to improve cardiovascular safety evaluation, either by investigating technological innovations or by adding mechanistic insight in emerging safety concerns, as observed in the field of cardio-oncology. Finally, in addition to its hands-on research pillar, INSPIRE will organize a number of summer schools and workshops that will be open to the wider community as well. In summary, INSPIRE aims to foster both research and training in safety pharmacology and hopes to inspire the future generation of safety scientists.
KW - Safety pharmacology
KW - Cardiovascular safety liabilities
KW - Cardio-oncology
KW - Drug development
KW - Training and education
KW - Methods
KW - Marie Sklodowska-curie actions
KW - CELL-DERIVED CARDIOMYOCYTES
KW - CLINICAL-TRIALS
KW - PRESSURE
KW - PARADIGM
KW - RODENTS
U2 - 10.1016/j.vascn.2020.106889
DO - 10.1016/j.vascn.2020.106889
M3 - Article
C2 - 32565326
VL - 105
JO - Journal of Pharmacological and Toxicological Methods
JF - Journal of Pharmacological and Toxicological Methods
SN - 1056-8719
M1 - 106889
ER -